Zinc Therapy in Critical Illness

Severe Sepsis Clinical Trial

Official title:

Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01162109
• Other study ID #: Zinc1017
• Secondary ID: 1K23HL105654
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 2010
• Est. completion date: December 2023

Study information

• Verified date: January 2023
• Source: University of Vermont
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sepsis is a clinical syndrome often caused by a bloodstream infection that results in a common set of symptoms termed systemic inflammatory response syndrome (SIRS). Severe sepsis (sepsis with organ failure) is the leading cause of death in critically ill patients in the US. Most patients with severe sepsis need to be treated in the intensive care unit with mechanical ventilation and intravenous antibiotics. Between 30 to 50% of all severe sepsis patients die and quality of life in survivors is substantially reduced. New therapies are needed to improve clinical outcomes in patients with sepsis. A new area of interest in the treatment of critical illness is pharmaconutrition, in which micronutrients (like zinc) are studied and administered to determine if they affect the inflammatory response or immunologic processes in critical illness. The FDA does not regulate micronutrients and does not require rigorous pharmacokinetic (the study of how a drug or nutrient is metabolized in the body) testing so it is not clear how to dose micronutrients in critically ill patients. It is also not clear if critically ill patients would metabolize these micronutrients differently than healthy people and would need different dosing levels. This is true of zinc, the focus of this research study. Zinc is essential for normal immune function, oxidative stress response, and wound healing, and its homeostasis is tightly regulated. Zinc deficiency occurs in >10% of Americans and leads to loss of innate and adaptive immunity and increased susceptibility to infections. The symptoms of zinc deficiency are similar to many of the symptoms of SIRS and there is strong biologic rationale to suggest that the zinc deficiency seen in nearly all sepsis patients may contribute to the development of sepsis syndrome and to the "immunoparalysis" common in sepsis patients This study has three specific aims, 1) to perform a phase I dose-finding study of intravenous zinc in mechanically ventilated patients with severe sepsis; 2) to define the pharmacokinetic of intravenous zinc in mechanically ventilated patients with severe sepsis compared to healthy controls; and 3) to investigate the impact of zinc on inflammation, immunity, and oxidant defense in patients with severe sepsis. A total of 40 critically ill patients from the FAHC intensive care units and 15 healthy controls will be enrolled in the study. The critically ill patient population will be divided into 4 dosing groups of 10 subjects (7 randomized to zinc and 3 to saline placebo). Group 1 will receive 500mcg/kg IBW/day elemental zinc in divided doses every 8 hours. If the 50th percentile of the normal plasma zinc range (110mcg/dL) has not been achieved in all patients by 7 days and there are no safety concerns, sequential groups of patients will receive increasing doses in 250mcg increments to the ceiling dose. Groups 2 through 4 will receive 750, 1000, and 1250mcg/kgIBW/day elemental zinc, respectively. Each participant will receive the intravenous zinc or placebo for a total of 7 days unless they die or leave the ICU earlier. Pharmacokinetic testing will be obtained from 40 of the critically ill subjects and in 15 healthy controls. Additional blood will be drawn during the infusion protocol to investigate the impact of zinc on inflammation, immunity, and oxidant defense.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 55
• Est. completion date: December 2023
• Est. primary completion date: September 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Severe sepsis
• Requiring mechanical ventilation
• 18 years or older

Exclusion Criteria:

• >36 hours since meeting severe sepsis criteria4
• Expected ICU length of stay <72 hours
• Pre-existing gastrointestinal disease*
• Post-cardiac arrest with significant anoxic brain injury
• Creatinine clearance <40mL/min*
• Taking zinc supplement during past month*
• Has received zinc supplementation while hospitalized
• Pregnant or lactating*
• AIDS with CD4<200*
• Previous bone marrow or solid organ transplant*
• Receiving TPN with added zinc

Related Conditions & MeSH terms

• Critical Illness
• Sepsis
• Severe Sepsis

Intervention

Dietary Supplement:
• Zinc sulfate
A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops. A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis.

Locations

Country	Name	City	State
United States	University of Vermont College of Medicine	Burlington	Vermont

Sponsors (2)

Lead Sponsor	Collaborator
University of Vermont	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics/pharmacodynamics		Several time points over one week during critical illness
Secondary	Production of TNF-alpha by circulating monocytes		Study days 1, 3, and 7
Secondary	Production of IL-1beta by circulating monocytes		Study days 1, 3, and 7
Secondary	Production of IL-6 by circulating monocytes		Study days 1, 3, and 7
Secondary	Production of IL-8 by circulating monocytes		Study days 1, 3, and 7
Secondary	Plasma TNF-alpha		Study days 1, 3, and 7
Secondary	Plasma IL-1beta		Study days 1, 3, and 7
Secondary	Plasma IL-6		Study days 1, 3, and 7
Secondary	Plasma IL-8		Study days 1, 3, and 7
Secondary	Serum malondialdehyde (MDA)		Study days 1, 3, and 7
Secondary	Serum 8-hydroxydeoxyguanine (8-OHdG)		Study days 1, 3, and 7
Secondary	Neutrophil phagocytosis		Study days 1, 3, and 7